跳至主要内容
临床试验/NCT03250325
NCT03250325已完成1 期

Multi-center Phase I/II Study of NY-ESO-1 T Cell Receptor Gene Transferred T Lymphocytes in Patients with Synovial Sarcoma

Takara Bio Inc.5 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2017年9月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
8
试验地点
5
主要终点
(Phase I) Adverse event, mortality, severe adverse event, discontinuation due to adverse event, laboratory test values

研究概览

简要总结

The purpose of this study is to evaluate the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide pre-treatment.

详细描述

Following pre-treatment with cyclophosphamide, NY-ESO-1-specific T cell receptor (TCR) gene transduced T lymphocytes are transferred to human leukocyte antigen (HLA)-A*02:01 or HLA-A*02:06 positive patients with synovial sarcoma expressing NY-ESO-1, which are surgically unresectable and refractory to anthracycline therapy. The primary objective is to evaluate the safety in the phase 1 and the efficacy in the phase 2.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Sequential
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically confirmed synovial sarcoma
  • Surgically unresectable tumor
  • Progressing or recurrent synovial sarcoma which has been treated with 1-4 regimens of systemic chemotherapies including anthracycline
  • HLA-A*02:01 or HLA-A*02:06 positive
  • Tumor that express NY-ESO-1 by immunohistochemistry
  • ≥ 18 years of age
  • Measurable lesions that are evaluable by the RECIST ver1.1
  • ECOG Performance Status of 0, 1 or 2
  • No treatment such as chemotherapy and be expected to recover fully from the previous treatment at the time of the lymphocytes collection for manufacturing
  • Life expectancy ≥ 16 weeks after consent
  • No severe damage on the major organs (bone marrow, heart, lung, liver, kidney, etc) and meet the following lab value criteria; Total bilirubin ≤ 1.5 x upper limit of normal (ULN); AST(GOT), ALT(GPT) < 3.0 x ULN; Creatinine < 1.5 x ULN; 2,500/μL < WBC ≤ULN; Hemoglobin ≥ 8.0g/dL; Platelets ≥ 75,000/μL
  • Patients must be able to understand the study contents and to give a written consent at his/her free will. Additionally, if patients are below 20 years of age, proxies must be able to give a written consent.

排除标准

  • Patients with the following conditions are excluded from the study; Unstable angina, cardiac infarction, or heart failure; Uncontrolled diabetes or hypertension; Active infection; Obvious interstitial pneumonia or lung fibrosis by chest X-ray; Active autoimmune disease requiring steroids or immunosuppressive therapy.
  • Active metastatic tumor cell invasion into CNS
  • Active multiple cancer
  • Positive for HBs antigen or HBV-DNA observed in serum
  • Positive for HCV antibody and HCV-RNA observed in serum
  • Positive for antibodies against HIV or HTLV-1
  • Left Ventricular Ejection Fraction (LVEF) ≤ 50%
  • History of serious hypersensitivity reactions to bovine or murine derived substances.
  • History of hypersensitivity reaction to ingredients or excipients of investigational drugs used in this study
  • History of hypersensitivity reaction to antibiotics used in manufacturing for the investigational drug used in this study.
  • Pregnant females, lactating females (except when they cease and do not resume lactation) or female and male patients who cannot agree to practice the adequate birth control from the consent to 6 months after infusion of the investigational drug.
  • Clinically significant systemic illness that in the judgment of the PI or sub-investigator would compromise the patient's ability to tolerate protocol therapy or significantly increase the risk of complications.

研究组 & 干预措施

Split dose of 5x10^9 TBI-1301

Experimental

Split dose of 5x10^9 TBI-1301 will be administered intravenously for 2 days following cyclophosphamide pre-treatment 750 mg/m2/d for 2 days.

干预措施: TBI-1301 (Biological)

Split dose of 5x10^9 TBI-1301

Experimental

Split dose of 5x10^9 TBI-1301 will be administered intravenously for 2 days following cyclophosphamide pre-treatment 750 mg/m2/d for 2 days.

干预措施: Cyclophosphamide (Drug)

结局指标

主要结局

(Phase I) Adverse event, mortality, severe adverse event, discontinuation due to adverse event, laboratory test values

时间窗: 52 weeks

Confirm the toxicity profile, which is measured by the degree of grade and seriousness, duration, causality, classification, etc. of the adverse events.

(Phase I) Appearance of replication competent retrovirus (RCR) by PCR

时间窗: 52 weeks

Confirm that no replication competent retrovirus observed.

(Phase I) Blood kinetics of TBI-1301 by realtime-PCR

时间窗: 52 weeks

Evaluate persistence and expansion of transferred TBI-1301.

(Phase II) Overall response rate

时间窗: 52 weeks

Evaluate response rate by measuring response using RECIST v1.1 and irRECIST

(Phase I) Appearance of clonality by linear amplification mediated (LAM)-PCR

时间窗: 52 weeks

Confirm that no clonality is observed.

次要结局

  • (Phase I) Objective response rate(52 weeks)
  • (Phase I/II) Progression free rate(12 weeks)
  • (Phase I/II) Progression free survival(52 weeks)
  • (Phase I/II) Overall survival(52 weeks)
  • (Phase II) Adverse event, mortality, severe adverse event, discontinuation due to adverse event, laboratory test values(52 weeks)
  • (Phase II) Appearance of RCR(52 weeks)
  • (Phase II) Appearance of clonality (LAM-PCR)(52 weeks)
  • (Phase II) Blood kinetics of TBI-1301 by realtime-PCR(52 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验

招募中
1 期
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersSarcoma, SynovialSarcoma,Soft TissueMelanoma Stage IVTriple Negative Breast CancerMetastatic CancerNon Small Cell Lung CancerBladder Urothelial CarcinomaNeuroblastoma, MetastaticOvary Cancer
NCT05296564Hadassah Medical Organization3
已完成
1 期
NY-ESO-1-specific T Cell Receptor (TCR) T Cell in SarcomaBone SarcomaSoft Tissue Sarcoma
NCT03462316Sun Yat-sen University2
撤回
1 期
NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaAdult Synovial SarcomaMyxoid/Round Cell LiposarcomaRecurrent Adult Soft Tissue SarcomaStage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma
NCT02059850Fred Hutchinson Cancer Center
进行中(未招募)
1 期
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPlatinum-Sensitive Fallopian Tube CarcinomaPlatinum-Sensitive Ovarian CarcinomaPlatinum-Sensitive Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Fallopian Tube CarcinomaRefractory Ovarian CarcinomaRefractory Primary Peritoneal Carcinoma
NCT03691376Roswell Park Cancer Institute4
终止
1 期
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced CancerHLA-A*0201 Positive Cells PresentLocally Advanced Malignant NeoplasmNY-ESO-1 PositiveUnresectable Malignant NeoplasmSarcoma
NCT03240861Jonsson Comprehensive Cancer Center5